Education
About Us
Working with TipRanks
Follow Us
Enovis (ENOV)
NYSE:ENOV
ENOV Stock Chart & Stats
$21.77
$0.83(1.85%)
At close: 4:00 PM EST
$21.77
$0.83(1.85%)
Day’s Range― - ―
52-Week Range$21.00 - $44.76
Previous CloseN/A
Volume391.51K
Average Volume (3M)1.03M
Market Cap
$1.25B
Enterprise Value$2.65B
Total Cash (Recent Filing)$33.62M
Total Debt (Recent Filing)$1.44B
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Feb 26, 2026EPS Estimate
0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.75
Shares Outstanding57,189,380
10 Day Avg. Volume1,157,224
30 Day Avg. Volume1,031,613
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.95
Price to Sales (P/S)1.15
P/FCF Ratio-36.09
Enterprise Value/Market Cap2.13
Enterprise Value/Revenue1.19
Enterprise Value/Gross Profit2.04
Enterprise Value/Ebitda-2.68
Forecast
1Y Price Target
$45.20Price Target Upside107.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Operational Efficiency And Cash GenerationImproved gross margins, disciplined cost controls, and planned reductions in capital spending should bolster adjusted profitability and free cash flow conversion.
Product LaunchesPlanned reconstructive product launches, including the next-generation Arvis and an Optimys shoulder rollout, support potential sales expansion as commercial efforts broaden.
Valuation And Risk-rewardTrading at a substantial discount to small-cap MedTech peers creates an attractive risk-reward setup if execution on growth and margin improvement materializes.
Bears Say
Competition And Integration RiskCompetition from larger, well-capitalized device companies and ongoing integration risk from recent acquisitions could pressure market share and margin expansion.
Revenue Guidance And Order TimingTrimmed revenue guidance tied to temporary ordering softness and timing effects reduces sales visibility across multiple regions and product lines.
Scale And Product Offering GapsPerceived under-scaling, exposure to mature markets and tariffs, and the absence of a robotic reconstruction offering have contributed to investor discounting and constrained cash flow flexibility.
Enovis News
ENOV FAQ
What was Enovis’s price range in the past 12 months?
Enovis lowest stock price was $21.00 and its highest was $44.76 in the past 12 months.
What is Enovis’s market cap?
Enovis’s market cap is $1.25B.
When is Enovis’s upcoming earnings report date?
Enovis’s upcoming earnings report date is Feb 26, 2026 which is in 11 days.
How were Enovis’s earnings last quarter?
Enovis released its earnings results on Nov 06, 2025. The company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.649 by $0.101.
Is Enovis overvalued?
According to Wall Street analysts Enovis’s price is currently Undervalued.
Does Enovis pay dividends?
Enovis does not currently pay dividends.
What is Enovis’s EPS estimate?
Enovis’s EPS estimate is 0.84.
How many shares outstanding does Enovis have?
Enovis has 57,189,380 shares outstanding.
What happened to Enovis’s price movement after its last earnings report?
Enovis reported an EPS of $0.75 in its last earnings report, beating expectations of $0.649. Following the earnings report the stock price went down -9.749%.
Which hedge fund is a major shareholder of Enovis?
Currently, no hedge funds are holding shares in ENOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enovis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$45.20 (107.63% Upside)
$45.20 (107.63% Upside)
Blogger Sentiment
Bullish
ENOV Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $29.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 10.7%
Last 30 Days ▼ 10.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.07%
12-Months-Change
Fundamentals
Return on Equity
-51.11%
Trailing 12-Months
Asset Growth
-20.12%
Trailing 12-Months
Company Description
Enovis
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
ENOV Company Deck
ENOV Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects strong revenue growth, improved gross margins, and positive steps in innovation, particularly in international markets and the Arvis Ultra launch. However, the goodwill impairment and the impacts of tariffs and divestitures present significant challenges.View all ENOV earnings summariesENOV Stock 12 Month Forecast
Average Price Target
$45.20
▲(107.63% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---